The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Open accessAbstract
AIMS: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. METHODS: Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration. RESULTS: This study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was -1.7 kg (-2.1 to -1.4 kg) and -1.9 kg (-2.1 to -1.7 kg) for body weight (p < 0.001); -1.3 cm (-1.8 to -0.7 cm) and -1.3 cm (-1.7 to -1.0 cm) for waist circumference (p < 0.001); -0.2% (-0.7% to 0.3%; p = 0.45) and -0.3% (-0.7% to 0.0%; p = 0.08) for estimated total body fat; -0.007 (-0.011 to -0.004) and -0.008 (-0.010 to -0.006) for index of central obesity (p < 0.001); and -0.3 (-0.5 to 0.0; p = 0.07) and -0.4 (-0.7 to -0.1; p = 0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups. CONCLUSION: Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium glucose co-transporter 2 inhibitors have metabolic effects, including lowering of plasma glucose levels, and (modest) effects on body weight and blood pressure.11”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Amato, M. C., Giordano, C., Galia, M., Criscimanna, A., Vitabile, S., Midiri, M., Galluzzo, A., & for the AlkaMeSy Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1825 · Cited by 1,751
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Cefalu, W. T., Leiter, L. A., Yoon, K., Arias, P., NISKANEN, L. K., Xie, J., Balis, D. A., Canovatchel, W. J., & Meininger, G. E. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 723
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 492
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., FITCHETT, D. H., Hantel, S., Espadero, R.-M., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 409
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–166 of 166
Cardiovascular safety of therapies for type 2 diabetes
Gupta, P. K., & White, W. B. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1239707 · Cited by 10
Weight effects of antidiabetic agents
Higbea, A. M., Duval, C., Chastain, L. M., & Chae, J. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395694 · Cited by 9
Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances
Liu, Z., & Yang, B. (2018) · Current Drug Targets · doi:10.2174/1389450120666181217111500 · Cited by 8
Shah, S. R., Iqbal, S. M., Alweis, R. L., & Roark, S. F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1552830 · Cited by 7
The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Dhindsa, D. S., Sandesara, P. B., & Shapiro, M. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00160 · Cited by 9
Dhindsa, D. S., Mehta, A., Sandesara, P. B., Thobani, A., Brandt, S., & Sperling, L. S. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1197-6 · Cited by 9
Sanon, V., Patel, S., Sanon, S., Rodriguez, R., Pham, S., & Chilton, R. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s97619 · Cited by 6
“Weight loss and empagliflozin In contrast to other antiglycemic agents such as sulfonylureas, which are known to cause weight gain, the SGLT2 inhibitors have been shown to cause weight loss.(34) A recent meta-analysis showed that patients taking empagliflozin lost −1.”
ResultReducing Alzheimer’s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection
Alami, M., Morvaridzadeh, M., Khayari, A. E., Boumezough, K., Fatimy, R. E., Khalil, A., Fülöp, T., & Berrougui, H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102751 · Cited by 6
de la Flor, J. C., Morales, B. C., Velasco, E. B., Hernandez, M. R., González-Mariño, R. Z., Tudero, C. R., Benites-Flores, I. R., Espinoza, C. V., Terrones, M. C., Guldris, S. C., et al. (2024) · Medicina · doi:10.3390/medicina60122096 · Cited by 8
Erbay, İ., Güdül, N. E., Süner, A. F., Aladağ, P., Karacar, U., & Avcı, A. (2025) · Clinical Cardiology · doi:10.1002/clc.70190 · Cited by 6
Shigiyama, F., Hiruma, S., Hisatake, S., Shiraga, N., Ikeda, T., Hirose, T., & Kumashiro, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0640-4 · Cited by 6
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
Bramlage, P., Tittel, S. R., Wagner, C., König, K., Raddatz, D., Weber-Lauffer, R., Erath, D., Hilgenberg, J., Spies, C., Danne, T., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001486 · Cited by 6
Nigella sativa tea mitigates type-2 diabetes and edema: a case report
Choo, T. M. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-022-00678-8 · Cited by 6
SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 6
Kobalava, Z. D., & Kiyakbaev, G. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-79-91 · Cited by 7
Anti-Obesity Effects of Aloe Vera Whole Leaf and Sitagliptin in Diabetic Rats
Javaid, S., & Waheed, A. (2020) · Annals of Punjab Medical College · doi:10.29054/apmc/2020.1023 · Cited by 6
Zhao, Q., Cheng, Y., Xu, Y.-K., Zhao, Z.-W., Liu, C., Sun, T., & Zhou, Y.-J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.735637 · Cited by 6
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
Wesling, M., & D’Souza, J. J. (2022) · Drugs in Context · doi:10.7573/dic.2021-11-7 · Cited by 9
Radellini, S., Vigneri, E., Guarnotta, V., Pantò, F., & Giordano, C. S. D. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01056-4 · Cited by 5
Takeuchi, S., Kohno, T., Goda, A., Shiraishi, Y., Saji, M., Nagatomo, Y., Tanaka, T. D., Takei, M., Nakano, S., Soejima, K., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.024 · Cited by 5
Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
Sun, H. Y., Wang, Z., Wang, Y., Rong, H., Wang, D., Liu, X., Jin, K., Sun, Z., & Fan, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1009025 · Cited by 3
Shami, D. A., SOUSOU, J. M., Batarseh, E., & Al-Azrai, L. (2023) · Cureus · doi:10.7759/cureus.33484 · Cited by 5
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
Evans, M., Morgan, A. R., & Yousef, Z. R. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00678-z · Cited by 4
Werida, R. H., Khedr, N. F., Khairat, I., & Khedr, L. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178244 · Cited by 3
Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
Aziz, H., Noor, M., Ahmad, S. B., Ali, S., Farhat, K., & Siddiqi, F. A. (2023) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v73i3.9256 · Cited by 3
Sedej, S., Stockner, A., Schreiber, R., Diwan, A., Breinbauer, R., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02879-2 · Cited by 3
Computational structural studies of SGLT2-related polypharmacy
Lloyd, A. R., Austin‐Muttitt, K., & Mullins, J. G. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334656 · Cited by 4
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Garodia, N., Gupta, V., Canovatchel, W. J., Lokesh, B., & Santani, R. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_85_17 · Cited by 3
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
CHADEVE, A. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i5.36838 · Cited by 3
Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats
Ashraf, G. M., Alghamdi, B. S. A., Alshehri, F. S., Alam, M. Z., Tayeb, H. O., & Tarazi, F. I. (2020) · Current Gene Therapy · doi:10.2174/1566523220999201111195047 · Cited by 3
Kobalava, Z. D., & Kiyakbaev, G. (2018) · Kardiologiia · doi:10.18087/cardio.2018.1.10082 · Cited by 3
Baruah, M. P., & Kalra, S. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.2.113 · Cited by 3
Dissanayake, H. A., Dilrukshi, S., Ratnasamy, V., Soysa, P., Samarathunga, T., Bandara, P., Silva, L. D., & Katulanda, P. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.11.005 · Cited by 3
Akhanlı, P., Hepşen, S., ARSLAN, İ. E., Düğer, H., Bostan, H., Kızılgül, M., Uçan, B., & Çakal, E. (2023) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5683 · Cited by 2
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 3
SGLT2 Inhibitor: A Cardio-Renal Metabolic Pill
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230119 · Cited by 2
Каретникова, В. Н., Альбертовна, Х. А., Kochergina, A. M., Осокина, А. В., Gruzdeva, O. V., Golubovskaia, D. P., & Барбараш, О. Л. (2022) · Kardiologiia · doi:10.18087/cardio.2022.12.n1838 · Cited by 2
Buch, A., Eldor, R., Kis, O., Ben‐Yehuda, A., Green, G., Greenman, Y., & Barak, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2024.e41593 · Cited by 1
Caturano, A., Galiero, R., Simeon, V., Acierno, C., Nilo, D., Marrone, A., Trotta, M. C., Vetrano, E., Sardu, C., Russo, V., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104284 · Cited by 2
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Симаненкова, А. В., Minasyan, S. M., Каронова, Т. Л., Vlasov, T. D., Тимкина, Н. В., Константиновна, Х. А., Станиславовна, Ф. О., Shimshilashvili, A., Тимофеева, В. А., Borshchev, Y. Y., et al. (2021) · Diabetes Mellitus · doi:10.14341/dm12714 · Cited by 1
Jang, H. Y., Kim, I., & Oh, J. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102394 · Cited by 1
Alshahrani, O. A. S., & Almalki, M. S. (2024) · Cureus · doi:10.7759/cureus.65242 · Cited by 2
SGLT2-Inhibitoren bei diabetischer Nephropathie
Dumann, E., Haller, H. G., & Menne, J. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00410-0 · Cited by 1
SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method
Janknegt, R., Reinders, M., & Bianchi, R. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0750
Radellini, S., Vigneri, E., Guarnotta, V., Pantò, F., & Giordano, C. S. D. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01119-6 · Cited by 1
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity
(2019) · Case Medical Research · doi:10.31525/ct1-nct04043702
Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?
Pisano, G., Donato, F., Lombardi, R., Dondossola, D. E., Orsi, E., & Fracanzani, A. L. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.007
Combination of topiramate and empagliflozin is considered a good option for treatment of obesity
Younis, M. (2020) · Endocrine Abstracts · doi:10.1530/endoabs.70.aep501
Sedykh, D. Y., Кашталап, В. В., & Барбараш, О. Л. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-29-8-12
Delães, U. T. D. A., Vasconcelos, C., Santos, S. V., Delães, U. T. D. A., Vilela, A. S., Delães, U. T. D. A., de Faria, R., Delães, U. T. D. A., Reis, Á., & Delães, U. T. D. A. (2023) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v39i3.13641
Watkins, C., Schilling, Z., Kawalec, K., & Hulisz, D. T. (2023) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-023-00724-3
İnsülin 100 Yıllık Mucize Hormon
Cerit, E. T., Barlas, T., Atalar, K., Bahçelioğlu, M., Kaplanoğlu, G. T., Seymen, C. M., Erdem, H. B., Ergün, M. A., Demir, Ö., Gülbahar, Ö., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.871
Arterial hypertension in metabolic syndrome, 2024
Nussbaumerová, B., & Rosolová, H. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.018
Narayan, R., & Narayan, A. (2023) · Optician · doi:10.12968/opti.2023.267.6903.18
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2
Aristizabal-Colorado, D., Trujillo, D. A. V., del Castillo, S. S. F., Martinez, W. A. R., Badiel, M., & Abreu-Lomba, A. (2025) · Cureus · doi:10.7759/cureus.83416
Hierro‐Bujalance, C., Infante‐Garcia, C., del Marco, À., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martínez, P., Lubian-Lopez, S., & Garcı́a-Alloza, M. (2020) · Figshare · doi:10.6084/m9.figshare.12096507
Mariam, E., Siddiqi, F. A., Qureshi, M. N., Hassan, F., Yaseen, L., & Siddiqi, K. A. (2025) · Journal of Rawalpindi Medical College · doi:10.37939/jrmc.v29i4.2770
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w
Dolati, A., Ahmadimoghaddam, D., Zamanirafe, M., Rezaie, S., Khazaie, S., Mehrpooya, M., & Doostizadeh, M. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70047 · Cited by 1
Karimi, M., Tahmasebi, A., Ramezanipour, S., Rad, F. N., Valizadeh, F., Abedi, P., Gholami, M., Ardekani, N. S., & Pirshahid, M. E. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70294
Ishiwata, S., Kasai, T., Sato, A., Suda, S., Matsumoto, H., Shitara, J., Yatsu, S., Murata, A., Shimizu, M., Kato, T., et al. (2026) · Sleep And Breathing · doi:10.1007/s11325-026-03780-2
Metadata
- Authors
- Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Norway) (NO)
- Corresponding author
- Neeland, Ian J
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-12-01
- Volume
- 13
- Issue
- 2
- Pages
- 119-126
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- PMC
- PMC4768401
- OpenAlex
- W2294512307
- Cited by
- 168
- References
- 25
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 11 · 2023: 19 · 2022: 18 · 2021: 20 · 2020: 24 · 2019: 17 · 2018: 18 · 2017: 9 · 2016: 11 · 2015: 2
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetes and Vascular Disease Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK106520)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- empagliflozin, type 2 diabetes, weight loss, adiposity, waist circumference, visceral fat, abdominal obesity, total body fat, SGLT2 inhibitors, cardiometabolic risk
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Weight Loss, Body Mass Index, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
